[PDF] Top 20 ANALYSIS OF mRNA TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS

ANALYSIS OF mRNA TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS

... no mRNA BCR/ABL híbrido, que caracteriza a leucemia mielóide crônica (CML), em material proveniente de 33 pacientes (22 homens e 11 ...observado mRNA do tipo b3a2, em 13 (39,4%) mRNA b2a2 e em 6 ... See full document

6

Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant

... digested in 40 to 50 µL lysis buffer (100 mM NaCl, 10 mM Tris HCl, pH ...µL of the digestion mixture was submitted to nested ...sets of synthetic oligonucleotides were performed in this ... See full document

11

Microsatellite instability and cytogenetic survey in myeloid leukemias

... occurs in hereditary nonpolyposis colorectal ...found in many sporadic cancers. In order to evaluate the importance of this process in myeloid leukemias, we studied five loci ... See full document

7

J. Bras. Patol. Med. Lab. vol.53 número3

... Introduction: Chronic myeloid leukemia (CML) is a genetic disorder of hematopoietic stem cells, resulting in a myeloproliferative expansion of blood ...presence of the ... See full document

6

Pharmaceutical care and home delivery of medication to patients with chronic myeloid leukemia

... La dispensación mensual de la medicación, puede suponer un inconveniente para determinados pacientes crónicos. Existe la posibilidad de disminuir la frecuenta- ción a los servicios de farmacia aumentando la cantidad de ... See full document

10

Rev. Bras. Hematol. Hemoter. vol.27 número3

... Chronic Myeloid Leukemia (CML) is a clonal disease characterized by balanced translocation between chromosomes 9 and 22 (Philadelphia ...inhibitor of all ABL related kinases. Ninety-eight CML ... See full document

7

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

... goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required life- long ...goal in clinical practice, and several tyrosine kinase ... See full document

8

Rev. Bras. Hematol. Hemoter. vol.35 número2

... total analysis time of 13 minutes per ...from patients being treated with imatinib ...developed in this study was successfully validated and is being eficiently used to measure imatinib ... See full document

6

Rev. Bras. Hematol. Hemoter. vol.35 número2

... Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to control ... See full document

2

Detection of mutator phenotype in Brazilian patients with acute and chronic myeloid leukemia

... found in the AML patients had greater lengths than those of the respective control sample, while CML patients had two larger and two smaller new al- leles in the tumoral tissue, as ... See full document

6

Rev. Bras. Hematol. Hemoter. vol.35 número6

... issue of the Revista Brasileira de Hematologia e Hemoterapia carries an article entitled “Chronic myeloid leukemia: an overview of the determinants of effectiveness and ... See full document

2

Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis

... cytometry in the peripheral blood of 84 chronic myeloid leukemia (CML) patients and 65 healthy controls; and vascular endothelial growth factor (VEGF) by quantitative real- time ... See full document

6

Rev. Bras. Hematol. Hemoter. vol.33 número2

... study in chronic phase chronic myeloid leukemia (CML-CP): three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and ... See full document

9

Rev. Bras. Hematol. Hemoter. vol.37 número1

... out in the Centro de Hematologia do Vale (CHV). The CHV consists of medical oncohematologi- cal professionals from the following services: Pio XII Hospital in São José dos Campos and the Regional ... See full document

5

Rev. Bras. Hematol. Hemoter. vol.27 número1

... mutation of the TP53 gene and inactivation of the p53 protein are the most common alterations observed in human ...tumors. In leukemias these alterations are not very frequent, but they ... See full document

2

Rev. Bras. Hematol. Hemoter. vol.37 número1

... Background: Chronic myeloid leukemia is a myeloproliferative disorder characterized by the Philadelphia chromosome or ...resulting in the break-point cluster region- Abelson tyrosine kinase ... See full document

4

Prognostic Value of CD11b Expression Level for Acute Myeloid Leukemia Patients: A Meta-Analysis.

... role of CD11b expression level in AML patients have enrolled participants with different ethnicity and different subtypes, adopted varied cut- off value for CD11b positivity ranging from 20% to 32% ... See full document

14

Rev. Bras. Hematol. Hemoter. vol.26 número4

... management of CML has become more complex The role of peripheral-blood progenitor cell (PBPC) transplantation as a treatment for chronic myeloid leukemia (CML) patients remains ... See full document

7

Clinics vol.70 número8

... 25 chronic myeloid leukemia patients who had been previously treated with imatinib and a second tyrosine kinase ...Nine patients were switched to dasatinib, and 16 patients were ... See full document

6

Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients.

... introduction of tyrosine kinase inhibitor drugs, that have dramatically improved the prognosis of CML patients, many problems remain to be solved because of the inability of these drugs ... See full document

13